Although at enrollment, patients had no known coronary heart disease, the risk of cardiovascu- lar events, including major coronary events and revascularization procedures, was also substan- tially reduced. On the basis of our data, 46 pa- tients (95 percent confidence interval, 24 to 243)would need to be treated for five years to prevent one stroke, 29 patients (95 percent confidence in- terval, 18 to 75) to prevent one major cardiovas- cular event, and 32 patients (95 percent confidence interval, 22 to 59) to avoid one revascularization procedure. These benefits were observed despite the increased use of open-label nonstudy statins during the study, a result suggesting that the effect is robust.